儿童肌肉骨骼损伤口服镇痛药:系统评价与网状Meta分析
该系统评价与网状Meta分析检索4个数据库至2023年3月,纳入8项开放随机对照试验、共1645例1月龄至18岁肌肉骨骼损伤患儿,比较口服镇痛药在门诊环境下的镇痛效果与不良事件。主要结局为60分钟和120分钟疼痛评分,次要结局为不良事件。结果显示布洛芬在120分钟疼痛缓解上显著优于对乙酰氨基酚(SMD 0.31)和阿片类(SMD 0.34),布洛芬-阿片联合也优于单用阿片类(SMD 0.19);60分钟时各干预无显著差异;布洛芬不良事件显著少于阿片类(RR 0.54)和布洛芬联合阿片类(RR 0.47)。作者结论为布洛芬是儿童肌肉骨骼损伤中最有效且不良事件最少的镇痛药。
要点
- 布洛芬在120分钟疼痛缓解上显著优于对乙酰氨基酚(SMD 0.31,95%CI 0.11-0.51;中等确定性)。
- 布洛芬在120分钟疼痛缓解上显著优于阿片类(SMD 0.34,95%CI 0.20-0.48;中等确定性)。
- 布洛芬联合阿片类在120分钟疼痛缓解上显著优于单用阿片类(SMD 0.19,95%CI 0.03-0.35)。
- 布洛芬不良事件显著少于阿片类(RR 0.54,95%CI 0.33-0.90)和布洛芬联合阿片类(RR 0.47,95%CI 0.25-0.89;中等确定性)。
- 60分钟时各疼痛干预之间无显著差异;纳入的8项RCT样本量相对较小,仅2项为高质量RCT。
适用人群与场景
- 1月龄至18岁、在门诊环境中因肌肉骨骼损伤就诊的儿童。
- 纳入标准:随机对照试验设计;年龄1月龄至18岁;肌肉骨骼损伤;门诊环境;有干预和对照;主要结局为60分钟和120分钟疼痛评分,次要结局为不良事件;全文且同行评议。
研究设计与关键结果
- 研究类型为系统评价与网状Meta分析,纳入8项开放随机对照试验、共1645例儿童,检索4个数据库至2023年3月。
- 布洛芬在120分钟疼痛缓解上显著优于对乙酰氨基酚(SMD 0.31,95%CI 0.11-0.51;中等确定性)和阿片类(SMD 0.34,95%CI 0.20-0.48;中等确定性)。
- 布洛芬联合阿片类在120分钟疼痛缓解上显著优于单用阿片类(SMD 0.19,95%CI 0.03-0.35)。
- 60分钟时各疼痛干预之间无显著差异。
- 布洛芬不良事件显著少于阿片类(RR 0.54,95%CI 0.33-0.90;中等确定性)和布洛芬联合阿片类(RR 0.47,95%CI 0.25-0.89;中等确定性)。
证据类型、等级与局限
- 证据类型:系统评价与网状Meta分析(纳入8项开放随机对照试验)。
- 采用推荐分级的评估、制定与评价(GRADE)工作组方法评估证据确定性,布洛芬对比对乙酰氨基酚、布洛芬对比阿片类、布洛芬对比布洛芬联合阿片类的不良事件结局为中等确定性。
- 局限:纳入的8项RCT样本量相对较小;仅2项为高质量RCT。
对床旁实践的改变
- 作者结论:网状Meta分析发现布洛芬是儿童肌肉骨骼损伤中最有效且不良事件最少的镇痛药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Pain in pediatric musculoskeletal (MSK) injuries can lead to increased anxiety, fear, and avoidance of medical care, making analgesic management critical. Therefore, we evaluated analgesic efficacy and adverse effects to select the optimal analgesic agent in pediatric patients with MSK injuries.
METHODS: Four databases were searched from inception to March 2023 for peer-reviewed, open randomized controlled trials (RCTs). Inclusion criteria were: (1) trials with RCT design, (2) children aged 1 month-18 years with MSK injury, (3) outpatient setting, (4) interventions and control, (5) primary outcome of pain score at 60 and 120 min and secondary outcome of adverse effects, and (6) full-text and peer-reviewed articles. Two reviewers screened, extracted data, and assessed the risk of bias. A frequentist random-effects network meta-analysis (NMA) was performed. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation working group approach.
RESULTS: We included eight trials comprising 1645 children. Ibuprofen was significantly associated with pain reduction at 120 min, compared with acetaminophen (SMD 0.31 [95% CI 0.11-0.51]; moderate certainty) and opioids (SMD 0.34 [95% CI 0.20-0.48]; moderate certainty). Compared with opioids alone, ibuprofen-opioid combination was significantly associated with pain reduction at 120 min (SMD 0.19 [95% CI 0.03-0.35]). No significant differences were found in pain interventions at 60 min. Ibuprofen had statistically fewer adverse events than opioids (RR, 0.54 [95% CI 0.33-0.90]; moderate certainty) and ibuprofen with opioids (RR 0.47 [95% CI 0.25-0.89]; moderate certainty). In terms of limitations, the eight RCTs included had relatively small sample sizes; only two were high-quality RCTs.
CONCLUSIONS: Our NMA found ibuprofen to be the most effective and least adverse analgesic in pediatric patients with MSK injuries.
参考来源
- Utsumi S, Amagasa S, Moriwaki T, et al. Oral analgesic for musculoskeletal injuries in children: A systematic review and network meta-analysis. Acad Emerg Med. 2023. PMID: 37688572. doi:10.1111/acem.14803
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。